MARKET

PDSB

PDSB

PDS Biotechnology Corporation
NASDAQ

Real-time Quotes | Nasdaq Last Sale

17.08
+1.09
+6.82%
After Hours: 17.08 0 0.00% 16:42 09/23 EDT
OPEN
16.30
PREV CLOSE
15.99
HIGH
17.50
LOW
16.08
VOLUME
486.38K
TURNOVER
--
52 WEEK HIGH
17.50
52 WEEK LOW
1.870
MARKET CAP
485.48M
P/E (TTM)
-31.1168
1D
5D
1M
3M
1Y
5Y
Shares of PDS Biotechnology Corporation (PDSB) Have Risen Above Previous 52-Week High
(MENAFN - Investor Brand Network) PDS Biotechnology Corporation (NASDAQ:PDSB) traded today at a new 52-week high of $16.94. This new high was reached on above average trading volume as 4 million shares traded hands, while the average 30-day volume is app...
MENAFN · 2h ago
PDS Biotechnology Corporation: 52-Week High Recently Eclipsed (PDSB)
(MENAFN - Investor Brand Network) Shares of PDS Biotechnology Corporation (NASDAQ:PDSB) traded at a new 52-week high today of $16.44. So far today approximately 4 million shares have been exchanged, as compared to an average 30-day volume of 480,000 shar...
MENAFN · 1d ago
PDS Biotechnology to Present at the Cantor Fitzgerald Virtual Global Healthcare Conference
PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies based on the Company's proprietary Versamune T-cell activating technology, today announced that its management will present at the Cantor...
GlobeNewswire · 1d ago
BRIEF-PDS Biotechnology Corp Achieves Safety Requirement Milestone For The First 12 Patients In Advanced Head And Neck Cancer
reuters.com · 3d ago
PDS Biotech Achieves Safety Requirement Milestone For the First 12 Patients in the VERSATILE-002 Phase 2 Combination Trial of PDS0101-KEYTRUDA® in Advanced Head and Neck Cancer
No dose limiting toxicities observed in initial group of 12 patientsFLORHAM PARK, N.J., Sept. 20, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies based on the C...
GlobeNewswire · 3d ago
PDS Biotechnology Meets Safety Requirement For Phase 2 Study On PDS0101-KEYTRUDA Combination
MT Newswires · 3d ago
Demand Continues to Grow for Crucial Medical Supplies
/PRNewswire/ -- The emergence of the pandemic has helped accelerate the growth of demand for diagnostic supplies such as ventilators, N95 masks, and PPE kits, which in turn is fueling the medical supplies market growth. The hospital medical equipment and s...
PR Newswire - PRF · 09/16 13:01
PDS Biotechnology to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies based on the Company's proprietary Versamune T-cell activating technology, announced today that its management will present at the Oppenh...
GlobeNewswire · 09/13 13:04
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of PDSB. Analyze the recent business situations of PDS Biotechnology Corporation through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 7 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average PDSB stock price target is 19.71 with a high estimate of 25.00 and a low estimate of 15.00.
EPS
Institutional Holdings
Institutions: 62
Institutional Holdings: 11.05M
% Owned: 38.89%
Shares Outstanding: 28.42M
TypeInstitutionsShares
Increased
9
565.98K
New
26
3.18M
Decreased
4
234.05K
Sold Out
12
601.25K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.87%
Pharmaceuticals & Medical Research
+1.27%
Key Executives
Non-Executive Chairman/Independent Director
Stephen Glover
President/Chief Executive Officer/Director
Frank Bedu-Addo
Chief Financial Officer/Chief Accounting Officer
Seth Van Voorhees
Chief Scientific Officer
Gregory Conn
Other
Lauren Wood
Director
Ilian Iliev
Independent Director
Kamil Ali-Jackson
Independent Director
Otis Brawley
Independent Director
Gregory Freitag
Independent Director
Richard Sykes
No Data
About PDSB
PDS Biotechnology Corp, formerly Edge Therapeutics, Inc., is an immuno-oncology company, The Company is focused on developing a pipeline of clinical-stage immunotherapies. Its therapies are developed for the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Versamune is its synthetic lipid-based immunotherapy platform. Its lead product candidate, PDS0101, is an off the shelf immunotherapeutic that is administered by subcutaneous injection. Its pipeline also includes PDS0102, PDS0103 and PDS0104. Its pipeline of Versamune-based products are all administered by subcutaneous injection .DS0102 is being developed for the treatment of prostate and breast cancers. PDS0103 is based on novel agonist antigens of the mucin-1 (MUC-1) oncogenic C-terminal region. PDS0104 is being developed for the treatment of melanoma.

Webull offers kinds of PDS Biotechnology Corp stock information, including NASDAQ:PDSB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PDSB stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading PDSB stock methods without spending real money on the virtual paper trading platform.